News:

Endpoints News: Takeda joins forces with small private biotech for preclinical Alzheimer’s research

Takeda is wading deeper into Alzheimer’s disease research with a new preclinical collaboration announced Tuesday. The company will work with...
Read More
1 3 4 5 6 7 41

TREVENTIS™ utilizes a proprietary, patented discovery engine – Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets.

CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets.

Our Takeda-partnered lead program focuses on anti-misfolding small molecules in Alzheimer’s disease. We have further CCM-driven, U.S. DOD-funded efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology platform.

Treventis has active
druggable CCM models for

Tau
Alpha Synuclein
p53
Amylin
And the Potential to Make 160+ Others…

#pf-body .pf-caption img.blockImage { margin: 0!important; float: none; } #pf-body a.elementor-icon, #pf-body a.skip-link{display:none!important;} /*#pf-content img.pf-large-image {max-width:100%!important}*/ #pf-content img.mediumImage, #pf-content figure.mediumImage { margin-left: auto!important; margin-right: auto!important; clear: both!important; float: none!important; display: block!important; }